Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVN424 in Parkinson's Disease Patients With Motor Fluctuations
NCT04191577Phase 2Completed
- Sponsor
- Cerevance
- Start
- Dec 2019
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of solengepras in Parkinson's disease (PD) (3 arms), sponsored by Cerevance. Primary endpoint: Percentage of Participants With Treatment-emergent Adverse Events Related to Study Drug at Day 35. Started Dec 2019; status: completed.
02
Drugs
solengepras
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04191577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04191577.